Case Report
Published on 10 Jul 2024
Case report: Aggressive natural killer cell leukemia and refractory hemophagocytic lymphohistiocytosis in an adolescent
in Blood Cancer
Frontiers in Hematology
doi 10.3389/frhem.2024.1413794
- 526 views
- Frontiers in Hematology
- Blood Cancer
- Articles
Type at least 3 characters
47 articles
Articles
Review
Published on 08 Jul 2024
The sweet symphony of N-glycans in myeloid malignancies
in Blood Cancer
Frontiers in Hematology
doi 10.3389/frhem.2024.1415618
- 488 views
Original Research
Published on 20 Jun 2024
Effectiveness, safety, and tolerability of delayed dexamethasone, rituximab, and cyclophosphamide as first-line treatment in patients with Waldenström macroglobulinemia: data from the Sicilian Myeloma Network
in Blood Cancer
Frontiers in Hematology
doi 10.3389/frhem.2024.1425677
- 390 views
Brief Research Report
Published on 13 Jun 2024
First clinical experience of isatuximab safety and tolerability in relapsed and refractory multiple myeloma: real-world data from a compassionate use program in Germany
in Blood Cancer
Frontiers in Hematology
doi 10.3389/frhem.2024.1335161
- 496 views
Review
Published on 08 May 2024
AL amyloidosis: an overview on diagnosis, staging system, and treatment
in Blood Cancer
Frontiers in Hematology
doi 10.3389/frhem.2024.1378451
- 987 views
Clinical Trial
Published on 28 Mar 2024
Phase II single-arm study of a combination of obinutuzumab and venetoclax in early relapsed or refractory diffuse large B-cell lymphoma—final results of the AGMT NHL15B study
in Blood Cancer
Frontiers in Hematology
doi 10.3389/frhem.2024.1331008
- 685 views
Case Report
Published on 21 Mar 2024
Case report: Donor lymphocyte infusion and blinatumomab as treatment for acute lymphoblastic leukemia relapse after allogeneic hematopoietic stem cell transplantation
in Blood Cancer
Frontiers in Hematology
doi 10.3389/frhem.2024.1345884
- 604 views
Opinion
Published on 18 Mar 2024
The impact of NETosis on hematological malignancies as a promising therapeutic target
in Blood Cancer
Frontiers in Hematology
doi 10.3389/frhem.2024.1377806
- 732 views
- 1 citation
Case Report
Published on 06 Mar 2024
Case report: A patient with ALK-positive large B-cell lymphoma benefited from myeloma-like treatment combined with the ALK inhibitor lorlatinib
in Blood Cancer
Frontiers in Hematology
doi 10.3389/frhem.2024.1334577
- 712 views
Review
Published on 19 Feb 2024
Hypersialylation and multiple myeloma
in Blood Cancer
Frontiers in Hematology
doi 10.3389/frhem.2024.1360149
- 1,616 views
Review
Published on 15 Feb 2024
Research and clinical updates on IRAK4 and its roles in inflammation and malignancy: themes and highlights from the 1st symposium on IRAK4 in cancer
in Blood Cancer
Frontiers in Hematology
doi 10.3389/frhem.2024.1339870
- 3,161 views
- 4 citations
Review
Published on 02 Feb 2024
How artificial intelligence revolutionizes the world of multiple myeloma
in Blood Cancer
Frontiers in Hematology
doi 10.3389/frhem.2024.1331109
- 2,335 views
- 3 citations
Brief Research Report
Published on 25 Jan 2024
Concanavalin A staining: a potential biomarker to predict cytarabine sensitivity in acute myeloid leukemia
in Blood Cancer
Frontiers in Hematology
doi 10.3389/frhem.2023.1302328
- 1,020 views
- 1 citation
Review
Published on 25 Jan 2024
De novo drug design through artificial intelligence: an introduction
in Blood Cancer
Frontiers in Hematology
doi 10.3389/frhem.2024.1305741
- 4,833 views
- 1 citation
Mini Review
Published on 04 Dec 2023
Bcl-2 inhibition in the treatment of hematologic malignancies
in Blood Cancer
Frontiers in Hematology
doi 10.3389/frhem.2023.1307661
- 1,116 views
- 1 citation
Mini Review
Published on 28 Nov 2023
Mini review: Advances and challenges in CAR-T cell therapy: from early chimeric antigen receptors to future frontiers in oncology
in Blood Cancer
Frontiers in Hematology
doi 10.3389/frhem.2023.1217775
- 1,099 views